All AbMole products are for research use only, cannot be used for human consumption.
Cyclophosphamide inhibits the AChE reversibly with an IC50 of 511 microM. The Michaelis-Menten constant (Km) was 132 microM for AChE in the control system; a value increased by 78% in the CP treated system. The Vmax was 73.8 mumol/h/mg protein for the control system. It works by sticking to one of the cancer cell's DNA strands.
*The compound is unstable in solutions, freshly prepared is recommended
 |
Source | Mol Cancer Ther (2015). Figure 5.Cyclophosphamide |
| Method | i.p. | |
| Cell Lines | NCR/nu and nu/nu nude mice | |
| Concentrations | 170 mg/kg | |
| Incubation Time | 24 h | |
| Results | Cyclophosphamide induced a significant increase of DiI5-liposome MFI at each of the distances from blood vessels analyzed. |
 |
Source | Mol Cancer Ther (2015). Figure 1.Cyclophosphamide |
| Method | i.p. | |
| Cell Lines | NCR/nu and nu/nu nude mice | |
| Concentrations | 170 mg/kg | |
| Incubation Time | 24 h | |
| Results | BT474-M3 tumor–bearing mice were predosed with cyclophosphamide (170 mg/kg) 2 to 5 days before injection of HER2-tPLD or free doxorubicin (both at 3 mg/kg). |
| Cell Experiment | |
|---|---|
| Cell lines | CD4+ T-cell |
| Preparation method | Total CD4+ T cells, labeled with αCD25 BV605, were cultured for 3 days in RPMI/10% AB containing 0 or 50 IU/mL IL-2 as indicated, in presence of CPA (0 μM-1000 μM), mafosfamide (MAF; stabilized active derivative of CPA) (0 μM, 1.2 μM, 12 μM), and/or verapamil (10 μM). Doses of CPA and MAF were titrated to identify doses discriminating sensitivity of Treg and non-Treg cell subsets. |
| Concentrations | 0 μM, 1.2 μM, 12 μM |
| Incubation time | 3 d |
| Animal Experiment | |
|---|---|
| Animal models | Sprague–Dawley rats |
| Formulation | |
| Dosages | 25mg/kg |
| Administration | i.v. |
| Molecular Weight | 261.09 |
| Formula | C7H15Cl2N2O2P |
| Solubility (25°C) | DMSO 35 mg/mL Water 30 mg/mL |
| Storage | 2-8°C |
[2] al-Jafari AA, et al. Toxicology. Inhibition of human acetylcholinesterase by Cyc-pham.
| Related DNA/RNA Synthesis Products |
|---|
| Clofarabine
Clofarabine inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. |
| Gemcitabine Hydrochloride
Gemcitabine (Gemzar, LY188011) inhibits DNA synthesis with an IC50 of 0.06 µM. |
| Nelarabine
Nelarabine is a novel purine antimetabolite antineoplastic agent. |
| Mizoribine
Mizoribine (Bredinin) is an imidazole nucleoside and an immunosuppressive agent with an IC50 of approximately 100 μM. Mizoribine inhibits replication of SARS-CoV with IC50s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively. |
| Capecitabine
Capecitabine is an orally-administered chemotherapeutic agent. Capecitabine is a precursor, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Capecitabine may inhibit cytochrome CYP2C9 enzyme, and therefore increase levels of substrates such as phenytoin and other substrates of CYP2C9. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
